Helus Pharma

Contribute to groundbreaking mental health research. Join Helus clinical trials exploring CYB003 for depression relief and CYB004 for anxiety treatment.

Helus’ development pipeline advances next-gen neuropsychiatry therapies for depression and anxiety. CYB003 and CYB004 are in clinical trials with positive early results.

Helus has developed EMBARK, a leading-edge model of psychotherapy born out of a desire to build upon the successes and avoid the shortcomings of previous approaches.

CYB003, a deuterated compound with FDA Breakthrough Therapy Designation, is in clinical trials for adjunctive treatment of Major Depressive Disorder.

Helus Pharma publishes research on next-generation therapies.

- With U.S. Food and Drug Administration (“FDA”) alignment on multisite, multinational Phase 3 program design Company expects to commence Phase 3 program around mid-year 2024 - - 15 U.S. clinical trials sites targeted; European sites to be added - - Robust and sustained improvement in depression

- Anxiety disorders are the most prevalent mental health disorders globally 1 , contributing to over 28 million disability-adjusted life years (“DALYs”) 2 - - Highly scalable intermittent treatment for Generalized Anxiety Disorder (“GAD”) with an expected treatment time of approximately 90-minutes

- Breakthrough Therapy Designation (“BTD”) provides an expedited review pathway, as well as increased access to U.S. Food and Drug Administration (“FDA”) guidance on trial design, with the potential to significantly reduce drug development timelines - - First known BTD granted by the FDA for an

Join Helus, an Equal Opportunity Employer, revolutionizing mental healthcare and developing next-generation neuropsychiatry therapies.

The Helus team brings together leaders in science, medicine, and business to deliver next-generation mental health treatments.

Explore Helus innovative drug discovery platform with robust intellectual property. Discover over 50 patent filings across 6 families, powering 7 research programs.

Helus develops patient-focused mental health treatments that improve access, optimize delivery, and support long-term recovery for underserved populations.

Helus is advancing mental health treatments through novel, second-generation therapies, proprietary drug delivery systems, and patent-protected molecules.

Helus IRL Limited’s data protection policy addresses employee privacy and rights.

Helus IRL Limited’s privacy notice explains how it handles personal data as a data controller.

Helus Pharma’s privacy policy outlines data collection, usage, and disclosure practices for customers and website users.